Switching lamivudine with adefovir dipivoxil combination therapy to entecavir monotherapy provides better viral suppression and kidney safety

Most chronic hepatitis B (CHB) patients in China are primitively treated with a combination of lamivudine (LAM) and adefovir dipivoxil (ADV). Although antiviral resistance can be avoided with this combination therapy, using it can have harmful side effects related to ADV, specifically kidney and bone injury.